CSL has gone outside the company, and outside the plasma industry, for its next leader. The biotech’s board has appointed Deborah Waterhouse, chief executive of GSK-controlled ViiV Healthcare, as chief executive and managing director from 1 February 2027. Reuters reported she will be the first woman to lead CSL since it was incorporated more than three decades ago.

The career

According to CSL, Ms Waterhouse has spent more than 25 years running parts of complex global specialty pharmaceutical businesses across the US, the UK, continental Europe and Australia, all within GSK. She joined in sales and marketing roles in the UK in the 1990s, led GSK’s HIV business in the UK and Europe, and was general manager for Australia and New Zealand from 2008 to 2012. She then ran central and eastern Europe and GSK’s US vaccines and US primary care units before becoming chief executive of ViiV in 2017. She is also president of GSK Global Health.

ViiV, majority owned by GSK with Shionogi as a shareholder, had sales of £7.7 billion in GSK’s 2025 financial year, CSL said. Fierce Pharma noted that during her tenure GSK’s HIV business pioneered the first two-drug HIV treatment regimens, the first long-acting HIV medication and the first long-acting prevention option. She has also been a non-executive director of Schroders (2019 to 2025) and, since July 2026, of Reckitt.

Why CSL chose her

“In February this year we said CSL’s next chief executive would need the ability to continue the momentum of our commercial performance, renew our pipeline and simplify our operations without losing the science and purpose that built this great company,” chair Brian McNamee said. “Deborah has done all those things on multiple occasions.” He said the board’s decision was unanimous.

“CSL is one of the great companies in our industry, and I saw what it means to Australia when I lived and worked in Melbourne,” Ms Waterhouse said. “The foundations are strong. My job is to continue the momentum and evolve the path into reliable growth for patients and shareholders.”

What she inherits

Reuters reported that the appointment followed a months-long search after the abrupt departure of former chief executive Paul McKenzie in February, amid investor frustration over the falling share price. CSL reported a net loss of $2.6 billion in the 2026 financial year, its first annual loss since listing in 1994, driven by $7.1 billion of impairments mostly related to its 2022 purchase of Vifor, and has announced plans to cut 3,000 jobs. Sentiment has since improved after CSL forecast growth for 2027, with the shares more than doubling from a decade low in June, Reuters said.

Analysts at Citi said her record at ViiV showed an ability to run a global business in a highly competitive market. “Ms. Waterhouse has been thorough and consistent, and demonstrated sound commercial acumen,” they wrote. Marc Jocum, senior ETF strategist at Global X, said her challenge would be to “turn the share price recovery into a sustained turnaround in earnings, restore investor confidence and convince the market that CSL’s best days are still ahead”.

The terms

Ms Waterhouse will stay based in the UK and spend significant time in Australia, the US and CSL’s major markets. Her contract sets a base salary of £1.5 million, a short-term incentive of 120% of base salary at target, and a long-term incentive of 250% at target. CSL will grant restricted stock units worth £7.71 million to replace GSK awards she forfeits. Because of her previous role in a competing business, she is restricted from involvement in the CSL Seqirus vaccines business until 31 March 2027. Interim chief executive Gordon Naylor will hand over and return to the board as a non-executive director.

Sources: CSL ASX announcement, 21 October 2026; Reuters, via KSL (21 October 2026); Fierce Pharma (21 October 2026).